GlassScriptPhysician profile
George R Murphy
NPI 1699789248
$1,035.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $275 · 2021: $51.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $168.98 | 2019-2020 | |
| Pfizer INC. | $163.42 | 2019-2020 | |
| Amgen INC. | $97.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $85.84 | 2019-2021 | |
| Lilly USA, LLC | $81.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.81 | 2019-2020 | |
| Abbvie INC. | $42.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.20 | 2019-2020 | |
| Shionogi INC | $22.45 | 2019 | |
| Eisai INC. | $17.84 | 2021 | |
| Astellas Pharma US INC | $16.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.